Marshall Wace’s TG Therapeutics TGTX Stock Holding History

Marshall Wace’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$316K	Sell	5,758 -19,935	-78%	-$816K	﹤0.01%	2700
2026 Q1	$854K	Buy	+25,693	New	+$766K	﹤0.01%	2208
2024 Q3	–	Sell	-2,051,762	Closed	-$36.5M	–	2950
2024 Q2	$36.5M	Buy	+2,051,762	New	+$32.7M	0.05%	330
2024 Q1	–	Sell	-1,020,102	Closed	-$17.4M	–	2798
2023 Q4	$17.4M	Buy	+1,020,102	New	+$11.9M	0.03%	514
2020 Q2	–	Sell	-24,637	Closed	-$242K	–	1935
2020 Q1	$242K	Buy	+24,637	New	+$311K	﹤0.01%	1146

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Marshall Wace's TGTX Position: Q2 2026 in Review

Marshall Wace reduced its TG Therapeutics (TGTX) stake by 78% in Q2 2026, selling an estimated $816K and leaving 5,758 shares worth $316K. The position accounts for ﹤0.01% of the portfolio, ranked #2700.

Marshall Wace first reported a position in TGTX in Q1 2020 and has held it in 5 quarters since. The position peaked at $36.5M in Q2 2024. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Marshall Wace held 5,758 shares of TG Therapeutics worth $316K as of Q2 2026.
Marshall Wace sold 19,935 TG Therapeutics shares in Q2 2026, an estimated $816K.
TG Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2700 holding.
Marshall Wace first reported a position in TG Therapeutics in Q1 2020 and has held it in 5 quarters since.
Marshall Wace's TG Therapeutics position peaked at $36.5M in Q2 2024.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.